目的 探讨复方双花片联合布地奈德治疗慢性咽炎的临床效果。方法 选取南阳市中心医院2016年2月-2017年2月收治的慢性咽炎患者101例，随机分成对照组（50例）和治疗组（51例）。对照组患者鼻腔雾化吸入布地奈德气雾剂，0.5 mg/次，3次/d。治疗组在对照组的基础上口服复方双花片，4片/次，3次/d。所有患者均经过规律治疗1周。评价两组患者临床疗效，同时比较治疗前后两组患者临床症状改善时间、血清炎性指标和不良反应差异。结果 治疗后，对照组和治疗组临床总有效率分别为82.00%、96.08%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组症状改善时间明显短于对照组患者，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者肿瘤坏死因子-α（TNF-α）、C反应蛋白（CRP）和IL-6水平均显著性降低，同组比较差异具有统计学意义（P<0.05）；且治疗组患者炎性指标水平明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗期间，对照组患者不良反应发生率为22.00%，明显高于治疗组的5.88%，两组不良反应比较差异具有统计学意义（P<0.05）。结论 复方双花片联合布地奈德治疗慢性咽炎疗效显著，安全性高，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Compound Shuanghua Tablets combined with budesonide in treatment of chronic pharyngitis. Methods Patients (101 cases) with chronic pharyngitis in Nanyang City Center Hospital from February 2016 to February 2017 were randomly divided into control (50 cases) and treatment (51 cases) groups. Patients in the control group were nasal cavity aerosol inhalation administered with Budesonide Aerosol, 0.5 mg/time, three times daily. Patients in the treatment group were po administered with Compound Shuanghua Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 1 week. After treatment, the clinical efficacy was evaluated, and the difference of the clinical symptom improvement time, serum inflammatory markers, and adverse reactions in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control and treatment groups were 82.00% and 96.08%, respectively, and there were differences between two groups (P<0.05). After treatment, the clinical symptom improvement time in the treatment group was obviously shorter than those in the control group, with significant difference between two groups (P<0.05). After treatment, the TNF-α, CRP, and IL-6 levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And these serum inflammatory markers in the treatment group were obviously lower than those in the control group, with significant difference between two groups (P<0.05). During the treatment, the incidence of adverse reactions in the control group was 22.00%, which were significantly higher than 5.88% in the treatment group, with significant difference between two groups (P<0.05). Conclusion Compound Shuanghua Tablets combined with budesonide has significant effect in treatment of chronic pharyngitis with high safety, which has a certain clinical application value.